País: Estados Unidos
Idioma: inglés
Fuente: NLM (National Library of Medicine)
POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152, CHLORIDE ION - UNII:Q32ZN48698), POTASSIUM BICARBONATE (UNII: HM5Z15LEBN) (POTASSIUM CATION - UNII:295O53K152), LYSINE HYDROCHLORIDE (UNII: JNJ23Q2COM) (LYSINE - UNII:K3Z4F929H6)
Qualitest Pharmaceuticals
POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 1.25 g
ORAL
PRESCRIPTION DRUG
INDICATIONS AND USAGE: 1. For therapeutic use in patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. 2. For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions: patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascities; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states. 3. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. CONTRAINDICATIONS: Potassium supp
HOW SUPPLIED: Effervescent Potassium/Chloride Tablets. Each tablet in solution provides 25 mEq potassium and chloride.
unapproved drug other
EFFERVESCENT POTASSIUM CHLORIDE- POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR ORAL SOLUTION TABLET, EFFERVESCENT QUALITEST PHARMACEUTICALS _Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been_ _approved by FDA. For further information about unapproved drugs, click here._ ---------- EFFERVESCENT POTASSIUM CHLORIDE PACKAGE INSERT DESCRIPTION: An oral potassium supplement. each effervescent tablet in solution provides the equivalent of 25 mEq (1865 mg) potassium chloride (supplied by 1.25 g potassium chloride, 0.7 g potassium bicarbonate and 1.5 g l-lysine monohydrochloride) with 0.77 g citric acid, FD and C Yellow No. 6 (Sunset Yellow), FD and C Yellow No. 6 Lake as color additives, natural and artificial flavor, and saccharin. CLINICAL PHARMACOLOGY: Potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in many essential physiological processes, such as the maintenance of intracellular tonicity, nerve impulse transmission, enzymatic reactions in intermediary metabolism, cardiac, skeletal and smooth muscle function, and the maintenance of normal renal function. Potassium depletion may occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Potassium depletion usually develops slowly as a result of lengthy therapy with oral diuretics, primary or secondary hyperaldosteronism, , diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion is additionally associated with severe diarrhea, accompanied by vomiting. Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may result in fatigue, weakness, nausea, drowsiness, loss of appetite, edema, oliguria, and chronic ileus with distention. Potassium deficiency may be manifested by shal Leer el documento completo